Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

Similar articles for PubMed (Select 21127411)

1.

Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease.

Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Patil S, Feldman DR, Reuter VE, Russo P, Motzer RJ.

Am J Clin Oncol. 2011 Oct;34(5):454-9. doi: 10.1097/COC.0b013e3181f47aa4.

2.

Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.

Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, Hsieh JJ, Molina AM, Patil S, Motzer RJ.

Ann Oncol. 2014 Mar;25(3):663-8. doi: 10.1093/annonc/mdt578. Epub 2014 Jan 23.

3.

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.

Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA.

Eur J Cancer. 2012 May;48(7):1031-7. doi: 10.1016/j.ejca.2012.02.050. Epub 2012 Mar 10.

PMID:
22409947
4.

Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.

Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM.

Am J Clin Oncol. 2013 Oct;36(5):450-4. doi: 10.1097/COC.0b013e3182546a91.

5.

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.

Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B.

J Clin Oncol. 2008 Jan 1;26(1):127-31. doi: 10.1200/JCO.2007.13.3223.

6.

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.

Molina AM, Feldman DR, Ginsberg MS, Kroog G, Tickoo SK, Jia X, Georges M, Patil S, Baum MS, Reuter VE, Motzer RJ.

Invest New Drugs. 2012 Feb;30(1):335-40. doi: 10.1007/s10637-010-9491-6. Epub 2010 Aug 14.

7.

Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.

Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin S, Swanson DA, Wood CG.

J Urol. 2007 Nov;178(5):1896-900. Epub 2007 Sep 17.

PMID:
17868729
8.

Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component.

Park I, Cho YM, Lee JL, Ahn JH, Lee DH, Song C, Hong JH, Kim CS, Ahn H.

J Cancer Res Clin Oncol. 2013 May;139(5):817-27. doi: 10.1007/s00432-013-1386-4. Epub 2013 Feb 9. Erratum in: J Cancer Res Clin Oncol. 2013 Oct;139(10):1777-9.

PMID:
23397357
9.

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI.

J Clin Oncol. 2009 Jan 10;27(2):235-41. doi: 10.1200/JCO.2008.18.0000. Epub 2008 Dec 8.

10.

Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.

Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, Platania M, Guadalupi V, Martinetti A, Bajetta E.

Oncology. 2007;73(3-4):204-9. doi: 10.1159/000127387. Epub 2008 Apr 16.

PMID:
18418013
11.

The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma.

Steiner T, Kirchner H, Siebels M, Doehn C, Heynemann H, Varga Z, Rohde D, Schubert J, Jocham D, Stief C, Fornara P, Hofmann R, Loening S, Roigas J.

J Cancer Res Clin Oncol. 2010 Jun;136(6):905-10. doi: 10.1007/s00432-009-0732-z. Epub 2009 Dec 12.

PMID:
20012752
12.

A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.

Tagawa ST, Milowsky MI, Jeske S, Mazumdar M, Kung S, Sung M, Lehrer D, Matulich D, Selzer J, Wright JJ, Nanus DM.

Am J Clin Oncol. 2011 Oct;34(5):443-8. doi: 10.1097/COC.0b013e3181e9c0d7.

PMID:
20881475
13.

Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.

Park JY, Lee JL, Baek S, Eo SH, Go H, Ro JY, Cho YM.

Hum Pathol. 2014 Jul;45(7):1437-44. doi: 10.1016/j.humpath.2014.02.019. Epub 2014 Mar 6.

PMID:
24784922
14.

Long-term response to sunitinib therapy for metastatic renal cell carcinoma.

Molina AM, Jia X, Feldman DR, Hsieh JJ, Ginsberg MS, Velasco S, Patil S, Motzer RJ.

Clin Genitourin Cancer. 2013 Sep;11(3):297-302. doi: 10.1016/j.clgc.2013.04.001. Epub 2013 May 24.

15.

Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib.

Kunene V, Miscoria M, Pirrie S, Islam MR, Afshar M, Porfiri E.

Clin Genitourin Cancer. 2014 Aug;12(4):251-5. doi: 10.1016/j.clgc.2013.12.001. Epub 2013 Dec 27.

PMID:
24560086
16.

Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.

Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, Keilholz U.

Oncology. 2009;76(5):350-4. doi: 10.1159/000209961. Epub 2009 Mar 24.

PMID:
19321976
17.
18.

Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.

Yuasa T, Tsuchiya N, Urakami S, Horikawa Y, Narita S, Inoue T, Saito M, Yamamoto S, Yonese J, Fukui I, Nakano K, Takahashi S, Hatake K, Habuchi T.

BJU Int. 2012 May;109(9):1349-54. doi: 10.1111/j.1464-410X.2011.10534.x. Epub 2011 Aug 25.

PMID:
21883864
19.

A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.

Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J.

Med Oncol. 2012 Jun;29(2):761-7. doi: 10.1007/s12032-011-9829-8. Epub 2011 Feb 6.

20.

Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.

Staehler M, Haseke N, Roosen A, Stadler T, Bader M, Siebels M, Karl A, Stief CG.

Eur J Med Res. 2010;15:287-91.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk